Auto-Injectors: A Revolutionary Leap In Drug Delivery

By Bill Welch, Executive Director of Services, Advanced Drug Delivery Segment, PCI Pharma Services

The global autoinjector market is expected to reach a value of USD 19.67 billion by 2028, driven by the increasing use of auto-injectors for self-administration of medications. Auto-injectors offer precise drug delivery, safety, reduced risk of contamination, and a patient-centric approach. PCI Pharma Services is a leader in advanced drug delivery solutions, providing expertise in device assembly and packaging. They focus on patient-centricity and optimized designs for manufacturability, offering guidance on device strategy and packaging design. PCI is expanding its capabilities and capacities for drug-device combination products, including auto-injectors, to meet the growing market demand.

As a global leading CDMO, PCI invests in scalable auto-injector assembly and labeling technologies to meet the rising demand. Their assembly line can accommodate various auto-injector types, making it suitable for development studies, clinical trials, and niche orphan drugs. They also have commercial assembly technologies for product launch and market supply. PCI aims to improve the lives of patients by providing sterile fill-finish, lyophilization, custom assembly, and packaging solutions. They have in-house laboratories for packaging and analytical services, ensuring regulatory compliance and patient safety through testing and adherence to ISO standards.

The widespread adoption of auto-injectors is transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety. Explore how PCI supports advanced drug delivery and aims to exceed customer expectations by delivering flexibility and excellence in all aspects of their services.